Filing Details

Accession Number:
0001562180-21-000880
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-03 20:02:46
Reporting Period:
2021-02-01
Accepted Time:
2021-02-03 20:02:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
897448 Amarin Corp Plc AMRN Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1289884 B Steven Ketchum C/O Amarin Pharma, Inc.
440 Us Highway 22
Bridgewater NJ 08807
Chief Scientific Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2021-02-01 16,703 $2.50 425,069 No 4 M Direct
Ordinary Shares Acquisiton 2021-02-01 164,573 $2.50 589,642 No 4 M Direct
Ordinary Shares Acquisiton 2021-02-01 11,082 $2.95 600,724 No 4 M Direct
Ordinary Shares Disposition 2021-02-01 192,358 $8.06 408,366 No 4 S Direct
Ordinary Shares Disposition 2021-02-01 25,370 $8.03 382,996 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Stock Option (Right to Buy) Disposition 2021-02-01 16,703 $0.00 16,703 $2.50
Ordinary Shares Stock Option (Right to Buy) Disposition 2021-02-01 164,573 $0.00 164,573 $2.50
Ordinary Shares Stock Option (Right to Buy) Disposition 2021-02-01 11,082 $0.00 11,082 $2.95
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2025-07-06 No 4 M Direct
0 2025-07-06 No 4 M Direct
0 2027-01-31 No 4 M Direct
Footnotes
  1. Multiple reportable transactions are reported in the Form 4 including exercises of previously granted stock options and sale of certain shares. The market sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
  2. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  3. On July 6, 2015, the Reporting Person was granted an option to purchase 180,000 Ordinary Shares under the Plan. The vesting of the shares was subject to a certain performance milestone that was previously achieved. The shares subject to this option vested in 48 equal monthly installments on the last day of each month starting on July 31, 2015. This option was fully vested as of the date hereof.
  4. On July 6, 2015, the Reporting Person was granted an option to purchase 240,000 Ordinary Shares under the Plan. The vesting of the shares was subject to a certain performance milestone that was previously achieved. The shares subject to this option vested in 48 equal monthly installments on the last day of each month starting on July 31, 2015. This option was fully vested as of the date hereof.
  5. On February 1, 2017, the Reporting Person was granted an option to purchase 133,000 Ordinary Shares under the Plan. The shares subject to this option vested in 48 equal monthly installments on the last day of each month starting on February 28, 2017. This option was fully vested as of the date hereof.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  8. Please see the section titled "Remarks" below for additional information.